Abstract
In contrast to the beneficial effects of tert-butylhydroquinone (tBHQ) as a food antioxidant, a number of studies have shown that chronic exposure to tBHQ may induce carcinogenicity. Therefore, we examined the ability of tBHQ to induce the cytochrome P450 1a1 (Cyp1a1), an enzyme known to play an important role in the chemical activation of xenobiotics to carcinogenic derivatives. A significant concentration-dependent increase in Cyp1a1 mRNA, protein, and activity occurred after treatment of murine hepatoma Hepa 1c1c7 cells with tBHQ. The increase in mRNA was apparent 3 h after treatment. The RNA polymerase inhibitor, actinomycin D, completely blocked the Cyp1a1 induction by tBHQ, indicating a requirement of de novo RNA synthesis through transcriptional activation. The protein synthesis inhibitor cycloheximide superinduced the tBHQ-mediated induction of Cyp1a1 mRNA and completely prevented the increase in Cyp1a1 activity, indicating that the induction of enzyme activity by tBHQ is dependent on de novo protein synthesis. In addition, the aryl hydrocarbon receptor (AHR) antagonist, resveratrol, inhibited the increase in Cyp1a1 activity by tBHQ. Gel electrophoretic mobility shift assays showed that tBHQ causes activation or transformation of the AHR in nuclear extracts, indicating that AHR-dependent mechanisms contributed to the Cyp1a1 induction. Similar to murine Hepa 1c1c7 cells, tBHQ caused a concentration-dependent increase in CYP1A1 at the mRNA and activity levels in human HepG2 cells. This is the first demonstration that the phenolic antioxidant, tBHQ, can directly induce Cyp1a1 gene expression in an AHR-dependent manner and may represent a novel mechanism by which tBHQ promotes carcinogenicity.
Footnotes
-
This work was supported by Natural Sciences and Engineering Research Council of Canada Grant RGPIN 250139 to A.O.S.E. N.G. is the recipient of the Province of Alberta Graduate Scholarship.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.104.002253.
-
ABBREVIATIONS: AHR, aryl hydrocarbon receptor; Act-D, actinomycin D; ARNT, aryl hydrocarbon receptor nuclear translocator; BHA, 3-tert-butyl-hydroxyanisole; tBHQ, tert-butylhydroquinone; CHX, cycloheximide; CYP1A1 or Cyp1a1, cytochrome P4501A1; EMSA, gel electrophoretic mobility shift assay; EROD, 7-ethoxyresorufin O-deethylase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HSP90, 90-kDa heat-shock protein; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Nrf2, nuclear factor erythroid 2-related factor 2; PCR, polymerase chain reaction; RT, reverse transcription; SSPE, sodium chloride/sodium phosphate/EDTA; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; XRE, xenobiotic response element.
- Received September 17, 2004.
- Accepted December 15, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|